click on circles to display study description...
pembrolizumab plus SoC (n=112) vs. placebo plus SoC (n=113)
randomized controlled trial
pembrolizumab
pembrolizumab along with combination therapy with paclitaxel plus carboplatin. The administration of pembrolizumab or placebo was planned in 6 cycles every 3 weeks, followed by up to 14 maintenance cycles every 6 weeks.
placebo
placebo along with combination therapy with paclitaxel plus carboplatin. The administration of pembrolizumab or placebo was planned in 6 cycles every 3 weeks, followed by up to 14 maintenance cycles every 6 weeks.
in Addition to Paclitaxel and Carboplatin
endometrial cancer
double-blind
395 sites in four countries (the United States, Canada, Japan, and South Korea
Interim analyses were scheduled to be triggered after the occurrence of at least 84 events of death or progression in the dMMR cohort and at least 196 events in the pMMR cohort.. The trial was temporarily paused to enrollment from April 2020 to November 2020 because of the coronavirus disease 2019
results from interim analysis
pembrolizumab plus SoC (n=295) vs. placebo plus SoC (n=296)
randomized controlled trial
pembrolizumab
pembrolizumab along with combination therapy with paclitaxel plus carboplatin. The administration of pembrolizumab or placebo was planned in 6 cycles every 3 weeks, followed by up to 14 maintenance cycles every 6 weeks.
placebo
placebo along with combination therapy with paclitaxel plus carboplatin. The administration of pembrolizumab or placebo was planned in 6 cycles every 3 weeks, followed by up to 14 maintenance cycles every 6 weeks.
in Addition to Paclitaxel and Carboplatin
endometrial cancer
Patients will be randomized in a 1:1 fashion to treatment arms 1 and 2 after prospectively stratifying them by mismatch repair deficiency(yes versus no), performance status (0 or 1 versus 2), and prior chemotherapy (yes versus no)
double-blind
395 sites in four countries (the United States, Canada, Japan, and South Korea
Interim analyses were scheduled to be triggered after the occurrence of at least 196 events in the pMMR cohort.. The trial was temporarily paused to enrollment from April 2020 to November 2020 because of the coronavirus disease 2019
results from interim analysis
pembrolizumab plus SoC (n=-9) vs. placebo plus SoC (n=-9)
randomized controlled trial
pembrolizumab
pembrolizumab: 200mg Q3W for 6 cycles and chemotherapy: (carboplatin area under the curve [AUC] 5 or 6 paclitaxel 175 mg/m2 Q3W or carboplatin AUC 2 or 2.7 paclitaxel 60 mg/m2 QW) in stage 1 / pembrolizumab: 400mg Q6W for 6 cycles in stage 2
placebo
placebo and chemotherapy: (carboplatin area under the curve [AUC] 5 or 6 paclitaxel 175 mg/m2 Q3W or carboplatin AUC 2 or 2.7 paclitaxel 60 mg/m2 QW) in stage 1 / placebo in stage 2
Adjuvant Chemotherapy With or Without Radiotherapy
endometrial cancer - (neo)adjuvant (NA)
double blind
result from press release (05/2024)
powered by vis.js Network